Population growth and aging, not rising age-standardized rates, drives the increase, with underlying causes varying widely by age and region.
|Articles|October 1, 1998
Supplements and Featured Publications
- Clinical and Economic Considerations of Antimicrobial Use
- Volume 4
- Issue 11 Suppl
Selected Abstracts
Advertisement
Articles in this issue
about 28 years ago
Optimizing Antimicrobial Therapy and Emerging Pathogensabout 28 years ago
Participating Facultyabout 28 years ago
Introductionabout 28 years ago
Mechanisms and Current Rates of Resistanceabout 28 years ago
Influence of Antibiotics on the Normal Floraabout 28 years ago
Therapeutic Pathways for Antimicrobial Use: General Overviewabout 28 years ago
Therapeutic Pathways for Antimicrobial Use: Pediatric Issuesabout 28 years ago
Pharmacoeconomic Impact of Appropriate Clinical PathwaysAdvertisement
Related to this article
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps in heart failure care.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."
The conference, held in New Orleans, Louisiana, by the American Academy of Ophthalmology, will offer 3 full days of content spanning from glaucoma to dry eye.
A JAMA analysis of 2021-2023 death records found heat-related mortality varied sharply by occupation and industry among working-age US adults.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
FDA Approves First Symptomatic Dermographism Treatment
3
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
4
FDA Approves Tucatinib Maintenance for HER2+ Metastatic Breast Cancer
5